Form 4: Theravance Biopharma CEO Rick Winningham Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
CEO Rick Winningham of Theravance Biopharma reports disposal of shares to cover tax obligations related to vesting restricted stock units.
Summary
- Rick E Winningham, CEO of Theravance Biopharma, reported a transaction on August 20, 2024.
- 15,997 ordinary shares were disposed of at a price of $8.22 to satisfy tax obligations.
- Following the transaction, Winningham directly owns 1,823,899 ordinary shares.
- He also indirectly owns 3,900 shares as custodian and 92,567 shares by trust.
Sentiment
Score: 7
Explanation: The document is a standard SEC filing related to stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction. The sentiment is neutral to slightly positive as it reflects standard corporate governance practices.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard transaction to cover tax obligations, which is a common practice among executives receiving stock-based compensation.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders as it is a routine disposal of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date of share disposal transaction. |
| 08/22/2024 | Date of signature on the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.